| WB | 1/500 - 1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200 - 1/1000 | Human,Mouse,Rat |
| ICC | 1/200 - 1/1000 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | IL6Q; gp80; CD126; HIES5; IL-6R; IL6RA; IL6RQ; IL-1Ra; IL-6RA; IL6QTL; IL-6R-1 |
| Entrez GeneID | 3570 |
| clone | 8F7G6 |
| WB Predicted band size | 52kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Purified recombinant fragment of human CD126 (AA: EXTRA 20-177) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于CD126(IL-6受体α链)抗体的3篇代表性文献，内容涵盖基础机制及临床应用：
---
1. **文献名称**：*Tocilizumab: A Review in Rheumatoid Arthritis*
**作者**：Scott LJ, et al.
**摘要**：综述抗CD126单抗托珠单抗(Tocilizumab)的作用机制及临床试验数据，证实其通过阻断IL-6信号通路显著改善类风湿性关节炎患者症状，并讨论其安全性与长期疗效。
---
2. **文献名称**：*IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-TNF biologics*
**作者**：Smolen JS, et al.
**摘要**：研究显示，托珠单抗在对抗肿瘤坏死因子(TNF)抑制剂无效的类风湿性关节炎患者中有效，通过靶向CD126抑制IL-6介导的炎症反应，提升临床缓解率。
---
3. **文献名称**：*Structure and function of interleukin-6 receptor complex*
**作者**：Yamasaki K, et al.
**摘要**：解析IL-6与CD126(IL-6Rα)及gp130蛋白的三维结构，阐明抗体阻断受体活性的分子机制，为靶向治疗提供结构生物学依据。
---
4. **文献名称**：*Interleukin-6 blockade as a therapeutic strategy in COVID-19-induced cytokine storm*
**作者**：Zhang C, et al.
**摘要**：探讨托珠单抗在COVID-19重症患者中的应用，通过抑制CD126减轻细胞因子风暴导致的过度炎症反应，改善患者预后。
---
以上文献涵盖基础研究、结构机制及多种疾病(如自身免疫病、病毒感染)的临床应用，反映CD126抗体的多效性治疗潜力。
CD126. also known as interleukin-6 receptor alpha (IL-6Rα), is a transmembrane protein that forms part of the receptor complex for interleukin-6 (IL-6), a pro-inflammatory cytokine. The IL-6 signaling pathway plays critical roles in immune regulation, inflammation, hematopoiesis, and metabolism. CD126 binds IL-6 and associates with the signal-transducing subunit gp130 (CD130), activating downstream pathways like JAK/STAT, MAPK, and PI3K. Dysregulation of IL-6 signaling is linked to autoimmune diseases (e.g., rheumatoid arthritis), cancers, and chronic inflammation.
CD126 antibodies are therapeutic or research tools targeting this receptor. Therapeutically, anti-CD126 antibodies (e.g., tocilizumab) block IL-6 binding, suppressing excessive inflammation. Tocilizumab is approved for rheumatoid arthritis, cytokine release syndrome, and juvenile idiopathic arthritis. In research, CD126 antibodies help study IL-6R expression patterns in immune cells, epithelial cells, and hepatocytes, or investigate IL-6’s role in diseases. Soluble IL-6R (sIL-6R), generated via alternative splicing or proteolytic cleavage, enables "trans-signaling" in cells lacking membrane-bound CD126. expanding IL-6’s pathogenic scope. Anti-CD126 antibodies may also target this soluble form to modulate trans-signaling. Challenges include balancing therapeutic efficacy with immunosuppressive risks and optimizing tissue-specific targeting. Ongoing research explores CD126’s involvement in conditions like COVID-19-associated cytokine storms and cancer progression, driving interest in refined antibody-based interventions.
×
